OPTIMIZATION IMMUNEPHARMACOTHERAPY OF PYOINFLAMMATORY DISEASES

Introduction: The results of clinical investigation of several pyoinflammatory diseases are presented. Objectives: On clinical data of various models of pyoinflammatory diseases - deep pyodermia (UCP), chronic salpingooforitis (OHSO), chronic pyelonephritis (CPN), authors found a significant mechanism of influence the pathogenesis on the manifestation of immunopathology, efficacy and mechanisms of pharmacological immunocorrection action. Methods: The study included 300 patients with purulent-inflammatory diseases of various genesis – UCP, CPN, OHSO. All the patients before and after traditional treatment with mono-and combination of immunomodulators of different origin – Roncoleukin, Licopide, Superlimph, Derinate, Polyoxidonium, Timogen, Galavit were subjected to a standard hemato-immunological examination and additionally model for each nosologic forms of diseases, bacteriological and clinical research. Mathematical analysis of obtained data was determined the significant differences of parameters from a predetermined level, and optionally, key, signal tests, formalized in the form of formulas. Results and Discussion: A significant impact of three types of the pathogenesis of inflammatory diseases on the nature and severity of the hemato-immunological disorders in patients are established; the effectiveness and mechanisms of action of the modulator Galavit; a lock of a normalizing effect of the traditional treatment of patients; increase activity due to additional assignments of 7 options of monocorrectors and three of their combinations; the ability of modulating drugs affect not only immunological, but also on haematological, bacteriological and clinical characteristics of patients. In results, authors are documented a hole effects the action of immune correcting drugs. A formalized assessment of the variations in clinical and laboratory parameters of patients allowed us to determine diagnostically significant target of each immune factor integrally to compare the effect of individual therapy, to establish mechanisms for the modification of the function of the lymphoid system in mono- and combination immune therapy, due to the inversion of mathematical analysis to identify laboratory evidence for selection of specific variants of complex treatment of patients. Conclusion: The result of clinical investigation and mathematical analysis of the results achieved was the formulation of a 6-level algorithm to identify and addressing treatment immunocompromising persons in the form of 7 approved programs for computer-based introduction to computer outcome of laboratory examination of patients